Is Novavax Stock a Buy?

In return, Novavax will get an influx of cash. Sanofi will pay $500 million upfront, and Novavax could get another $700 million depending on development and regulatory milestones. Novavax coulf also receive up to $200 million, plus royalties, "for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M adjuvant technology." The cash gives Novavax a lot more stability. It has previously raised a "going concern risk" about its business, which means there are doub ...